Caffeine consumption outcomes on amyotrophic lateral sclerosis disease progression and cognition
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Caffeine consumption does not impact Amyotrophic Lateral Sclerosis (ALS) progression or survival. However, higher caffeine intake is linked to better cognitive function in ALS patients with specific genetic variants, suggesting a potential pharmacogenetic strategy.
Area Of Science
- Neuroscience
- Genetics
- Pharmacology
Background
- Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease with poorly understood factors influencing its course.
- The role of caffeine consumption and its impact on ALS progression, survival, and cognitive function requires further elucidation.
- Genetic variations in caffeine metabolism may modulate its effects in neurological conditions.
Purpose Of The Study
- To investigate the association between regular caffeine consumption and clinical outcomes in Amyotrophic Lateral Sclerosis (ALS) patients.
- To determine if caffeine intake affects ALS progression, functional disability, survival, and cognitive performance.
- To explore the potential influence of genetic variants on caffeine's effects in ALS.
Main Methods
- A prospective multicenter study involving 378 ALS patients with detailed caffeine consumption data.
- Assessment of functional disability using the revised ALS Functional Rating Scale (ALSFRS-R) and cognitive function via the Edinburgh Cognitive and Behavioural ALS Screen (ECAS).
- Genotyping of 282 patients for single nucleotide polymorphisms in genes related to caffeine metabolism (CYP1A1, CYP1A2, AHR, POR, XDH, ADORA2A).
Main Results
- No significant association was found between caffeine consumption and ALS survival, functional disability, or disease progression.
- A notable positive correlation emerged between higher caffeine consumption and improved cognitive performance (ECAS scores) in patients with C/T and T/T genotypes at the CYP1A1 rs2472297 polymorphism.
- This specific genotype is associated with faster caffeine metabolism.
Conclusions
- Regular caffeine consumption appears safe concerning ALS progression and survival.
- Caffeine intake may offer a beneficial effect on cognitive function in ALS patients who are fast caffeine metabolizers, as indicated by the CYP1A1 rs2472297 genotype.
- These findings suggest a potential for pharmacogenetic therapeutic strategies involving caffeine in ALS management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...